Literature DB >> 32330238

Unexpected Results From a Phase 2 Trial of a Microbiome Therapeutic for Clostridioides difficile Infection: Lessons for the Future.

Vincent Bensan Young1.   

Abstract

Entities:  

Keywords:  Clostridiodes difficile; clinical trial; microbiome; microbiome therapy

Mesh：

Substances：

Year:  2020        PMID： 32330238      PMCID： PMC8204768          DOI： 10.1093/cid/ciaa476

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  14 in total

1.  Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis.

Authors:  B EISEMAN; W SILEN; G S BASCOM; A J KAUVAR
Journal:  Surgery       Date:  1958-11       Impact factor: 3.982

2.  Point-Counterpoint: What Is the Optimal Approach for Detection of Clostridium difficile Infection?

Authors:  Ferric C Fang; Christopher R Polage; Mark H Wilcox
Journal:  J Clin Microbiol       Date:  2017-01-11       Impact factor: 5.948

Review 3.  The role of the microbiome in human health and disease: an introduction for clinicians.

Authors:  Vincent B Young
Journal:  BMJ       Date:  2017-03-15

4.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

5.  High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection.

Authors:  A Wadhwa; M F Al Nahhas; R A Dierkhising; R Patel; P Kashyap; D S Pardi; S Khanna; M Grover
Journal:  Aliment Pharmacol Ther       Date:  2016-07-22       Impact factor: 8.171

6.  Practical characteristics of adaptive design in phase 2 and 3 clinical trials.

Authors:  A Sato; M Shimura; M Gosho
Journal:  J Clin Pharm Ther       Date:  2017-08-28       Impact factor: 2.512

7.  Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era.

Authors:  Christopher R Polage; Clare E Gyorke; Michael A Kennedy; Jhansi L Leslie; David L Chin; Susan Wang; Hien H Nguyen; Bin Huang; Yi-Wei Tang; Lenora W Lee; Kyoungmi Kim; Sandra Taylor; Patrick S Romano; Edward A Panacek; Parker B Goodell; Jay V Solnick; Stuart H Cohen
Journal:  JAMA Intern Med       Date:  2015-11       Impact factor: 21.873

8.  Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.

Authors:  Zachariah DeFilipp; Patricia P Bloom; Mariam Torres Soto; Michael K Mansour; Mohamad R A Sater; Miriam H Huntley; Sarah Turbett; Raymond T Chung; Yi-Bin Chen; Elizabeth L Hohmann
Journal:  N Engl J Med       Date:  2019-10-30       Impact factor: 91.245

Review 9.  How to: Establish and run a stool bank.

Authors:  E M Terveer; Y H van Beurden; A Goorhuis; J F M L Seegers; M P Bauer; E van Nood; M G W Dijkgraaf; C J J Mulder; C M J E Vandenbroucke-Grauls; H W Verspaget; J J Keller; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2017-05-19       Impact factor: 8.067

10.  SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.

Authors:  Barbara H McGovern; Christopher B Ford; Matthew R Henn; Darrell S Pardi; Sahil Khanna; Elizabeth L Hohmann; Edward J O'Brien; Christopher A Desjardins; Patricia Bernardo; Jennifer R Wortman; Mary-Jane Lombardo; Kevin D Litcofsky; Jonathan A Winkler; Christopher W J McChalicher; Sunny S Li; Amelia D Tomlinson; Madhumitha Nandakumar; David N Cook; Roger J Pomerantz; John G Auninš; Michele Trucksis
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079
View more
  1 in total

Review 1.  Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease.

Authors:  Jonathan P Segal; Benjamin H Mullish; Mohammed N Quraishi; Tariq Iqbal; Julian R Marchesi; Harry Sokol
Journal:  Therap Adv Gastroenterol       Date:  2020-09-03       Impact factor: 4.409
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.